TY - JOUR
T1 - Variations in the peroxisome proliferator-activated receptor-γ gene and melanoma risk
AU - Mössner, Rotraut
AU - Meyer, Peter
AU - Jankowski, Florian
AU - König, Inke R.
AU - Krüger, Ullrich
AU - Kammerer, Stefan
AU - Westphal, Götz
AU - Boettger, Melanie B.
AU - Berking, Carola
AU - Schmitt, Christina
AU - Brockmöller, Jürgen
AU - Ziegler, Andreas
AU - Stapelmann, Henrike
AU - Kaiser, Rolf
AU - Volkenandt, Matthias
AU - Reich, Kristian
N1 - Funding Information:
We thank Melanie Walter and Karoline Jobst for excellent technical assistance. This work was supported by a grant from the Kubeschka/Stricker/Wirth-Stiftung and the Frauenförderungsprogramm of the Georg-August-University, Göttingen (both to R.M.).
PY - 2007/2/8
Y1 - 2007/2/8
N2 - There is strong evidence to suggest that the peroxisome proliferator-activated receptor (PPAR)-γ, a member of the nuclear receptor family of transcriptional regulators, mediates tumor suppressive activities in a variety of human cancers. Recently, PPARγ agonists were found to inhibit growth of melanoma cell lines. Here, we tested the possibility that variations in the gene encoding PPARγ (PPARG) influence melanoma risk. Two variations of PPARG (P12A[rs1801282] and C161T [rs3856806]) were investigated in two independent case-control studies with a total of 832 melanoma patients and 790 control individuals. In the first study, homozygous carriers of the rare *T allele of the C161T polymorphism in exon 6 of PPARG were significantly more common among patients with melanoma than among healthy subjects (6.0 vs. 2.0%; P=0.0096) and this association was independent of clinical risk factors such as skin type and nevus count (odds ratio 5.18; 95% confidence interval 1.68-15.96; P=0.0041). This finding, however, could not be replicated in the second case-control study. We therefore conclude that the investigated PPARG polymorphisms are not likely to constitute a significant risk factor for the development of melanoma among German Caucasians.
AB - There is strong evidence to suggest that the peroxisome proliferator-activated receptor (PPAR)-γ, a member of the nuclear receptor family of transcriptional regulators, mediates tumor suppressive activities in a variety of human cancers. Recently, PPARγ agonists were found to inhibit growth of melanoma cell lines. Here, we tested the possibility that variations in the gene encoding PPARγ (PPARG) influence melanoma risk. Two variations of PPARG (P12A[rs1801282] and C161T [rs3856806]) were investigated in two independent case-control studies with a total of 832 melanoma patients and 790 control individuals. In the first study, homozygous carriers of the rare *T allele of the C161T polymorphism in exon 6 of PPARG were significantly more common among patients with melanoma than among healthy subjects (6.0 vs. 2.0%; P=0.0096) and this association was independent of clinical risk factors such as skin type and nevus count (odds ratio 5.18; 95% confidence interval 1.68-15.96; P=0.0041). This finding, however, could not be replicated in the second case-control study. We therefore conclude that the investigated PPARG polymorphisms are not likely to constitute a significant risk factor for the development of melanoma among German Caucasians.
UR - http://www.scopus.com/inward/record.url?scp=33845631553&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2006.02.022
DO - 10.1016/j.canlet.2006.02.022
M3 - Journal articles
C2 - 16713673
AN - SCOPUS:33845631553
SN - 0304-3835
VL - 246
SP - 218
EP - 223
JO - Cancer Letters
JF - Cancer Letters
IS - 1-2
ER -
